|
1
|
Gatta G, Capocaccia R, Stiller C, Kaatsch
P, Berrino F and Terenziani M: Childhood cancer survival trends in
Europe: a EUROCARE Working Group study. J Clin Oncol. 23:3742–3751.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buddingh EP, Anninga JK, Versteegh MI, et
al: Prognostic factors in pulmonary metastasized high-grade
osteosarcoma. Pediatr Blood Cancer. 54:216–221. 2010.PubMed/NCBI
|
|
3
|
Federman N, Bernthal N, Eilber FC and Tap
WD: The multidisciplinary management of osteosarcoma. Curr Treat
Options Oncol. 10:82–93. 2009. View Article : Google Scholar
|
|
4
|
Lewis IJ, Nooij MA, Whelan J, et al:
Improvement in histologic response but not survival in osteosarcoma
patients treated with intensified chemotherapy: a randomized phase
III trial of the European Osteosarcoma Intergroup. J Natl Cancer
Inst. 99:112–128. 2007. View Article : Google Scholar
|
|
5
|
Lau AN, Curtis SJ, Fillmore CM, et al:
Tumor-propagating cells and Yap/Taz activity contribute to lung
tumor progression and metastasis. EMBO J. 33:468–481. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen W, Wang W, Zhu B, et al: A functional
variant rs1820453 in YAP1 and breast cancer risk in Chinese
population. PLoS One. 8:e790562013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu MZ, Yao TJ, Lee NP, et al:
Yes-associated protein is an independent prognostic marker in
hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Orr BA, Bai H, Odia Y, Jain D, Anders RA
and Eberhart CG: Yes-associated protein 1 is widely expressed in
human brain tumors and promotes glioblastoma growth. J Neuropathol
Exp Neurol. 70:568–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosenbluh J, Nijhawan D, Cox AG, et al:
β-catenin-driven cancers require a YAP1 transcriptional complex for
survival and tumorigenesis. Cell. 151:1457–1473. 2012.
|
|
10
|
Edgar BA: From cell structure to
transcription: Hippo forges a new path. Cell. 124:267–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tapon N, Harvey KF, Bell DW, et al:
salvador promotes both cell cycle exit and apoptosis in
Drosophila and is mutated in human cancer cell lines. Cell.
110:467–478. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lai ZC, Wei X, Shimizu T, et al: Control
of cell proliferation and apoptosis by mob as tumor suppressor,
mats. Cell. 120:675–685. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sudol M: Yes-associated protein (YAP65) is
a proline-rich phosphoprotein that binds to the SH3 domain of the
Yes proto-oncogene product. Oncogene. 9:2145–2152. 1994.PubMed/NCBI
|
|
14
|
Fernandez-L A and Kenney AM: The Hippo in
the room: a new look at a key pathway in cell growth and
transformation. Cell Cycle. 9:2292–2299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu MZ, Yao TJ, Lee NP, et al:
Yes-associated protein is an independent prognostic marker in
hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu JY, Li YH, Lin HX, et al:
Overexpression of YAP 1 contributes to progressive features and
poor prognosis of human urothelial carcinoma of the bladder. BMC
Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Camargo FD, Gokhale S, Johnnidis JB, et
al: YAP1 increases organ size and expands undifferentiated
progenitor cells. Curr Biol. 17:2054–2060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gilgenkrantz H: The world according to
YAP: a continuous cross-talk between Wnt and Hippo pathways. Med
Sci. 29:868–874. 2013.(In French).
|
|
19
|
Clevers H: Wnt/β-catenin signaling in
development and disease. Cell. 127:469–480. 2006.
|
|
20
|
Wend P, Holland JD, Ziebold U and
Birchmeier W: Wnt signaling in stem and cancer stem cells. Semin
Cell Dev Biol. 21:855–863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi
X and Hoang BH: The Wnt signaling pathway: implications for therapy
in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kansara M, Tsang M, Kodjabachian L, et al:
Wnt inhibitory factor 1 is epigenetically silenced in human
osteosarcoma, and targeted disruption accelerates
osteosarcomagenesis in mice. J Clin Invest. 119:837–851. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang YH, Li B, Shen L, Shen Y and Chen
XD: The role and clinical significance of YES-associated protein 1
in human osteosarcoma. Int J Immunopathol Pharmacol. 26:157–167.
2013.PubMed/NCBI
|
|
24
|
Chan LH, Wang W, Yeung W, Deng Y, Yuan P
and Mak KK: Hedgehog signaling induces osteosarcoma development
through Yap1 and H19 overexpression. Oncogene. Oct 21–2013.(Epub
ahead of print).
|
|
25
|
Edgar BA: From cell structure to
transcription: Hippo forges a new path. Cell. 124:267–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao B, Wei X, Li W, et al: Inactivation
of YAP oncoprotein by the Hippo pathway is involved in cell contact
inhibition and tissue growth control. Genes Dev. 21:2747–2761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang X, George J, Deb S, et al: The Hippo
pathway transcriptional co-activator, YAP, is an ovarian cancer
oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Dong Q, Zhang Q, Li Z, Wang E and
Qiu X: Overexpression of yes-associated protein contributes to
progression and poor prognosis of non-small-cell lung cancer.
Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu JY, Li YH, Lin HX, et al:
Overexpression of YAP 1 contributes to progressive features and
poor prognosis of human urothelial carcinoma of the bladder. BMC
Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim JM, Kang DW, Long LZ, et al:
Differential expression of Yes-associated protein is correlated
with expression of cell cycle markers and pathologic TNM staging in
non-small-cell lung carcinoma. Hum Pathol. 42:315–323. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martins-Neves SR, Lopes AO, do Carmo A, et
al: Therapeutic implications of an enriched cancer stem-like cell
population in a human osteosarcoma cell line. BMC Cancer.
12:1392012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang CJ, Yang JY, Xia W, et al: EZH2
promotes expansion of breast tumor initiating cells through
activation of RAF1-β-catenin signaling. Cancer Cell. 19:86–100.
2011.PubMed/NCBI
|
|
33
|
Cordenonsi M, Zanconato F, Azzolin L, et
al: The Hippo transducer TAZ confers cancer stem cell-related
traits on breast cancer cells. Cell. 147:759–772. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou D, Zhang Y, Wu H, et al: Mst1 and
Mst2 protein kinases restrain intestinal stem cell proliferation
and colonic tumorigenesis by inhibition of Yes-associated protein
(Yap) overabundance. Proc Natl Acad Sci USA. 108:E1312–E1320. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ota M and Sasaki H: Mammalian Tead
proteins regulate cell proliferation and contact inhibition as
transcriptional mediators of Hippo signaling. Development.
135:4059–4069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Konsavage WM Jr, Kyler SL, Rennoll SA, Jin
G and Yochum GS: Wnt/β-catenin signaling regulates Yes-associated
protein (YAP) gene expression in colorectal carcinoma cells. J Biol
Chem. 287:11730–11739. 2012.
|
|
37
|
Burgess AW, Faux MC, Layton MJ and Ramsay
RG: Wnt signaling and colon tumorigenesis - a view from the
periphery. Exp Cell Res. 317:2748–2758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McQueen P, Ghaffar S, Guo Y, Rubin EM, Zi
X and Hoang BH: The Wnt signaling pathway: implications for therapy
in osteosarcoma. Expert Rev Anticancer Ther. 11:1223–1232. 2011.
View Article : Google Scholar : PubMed/NCBI
|
